Biomarker Landscape in Cancer Research.

Format:

Book

Author/Creator:

Shegokar, Ranjita.

Contributor:

Pathak, Yashwant.

Language:

English

Physical Description:

1 online resource (538 pages)

Edition:

1st ed.

Place of Publication:

Chantilly : Elsevier Science & Technology, 2025.

Summary:

Biomarker Landscape in Cancer Research examines the impact of early detection, predication of aggressiveness, and the determination of the best treatment for cancers.With a strong focus on the status, challenges, and prospects of biomarker measurements' tools and technology, the book also examines clinical translation-related knowledge and.

Contents:

Front Cover

Biomarker Landscape in Cancer Research

Copyright

Contents

Contributors

About the editors

Preface

Drug Delivery Systems Landscape in Cancer Research (Vol. 1)

Biomarker Landscape in Cancer Research (Vol. 2)

Diagnostics Landscape in Cancer Research (Vol. 3)

Preclinical Landscape in Cancer Research (Vol. 4)

Clinical Landscape in Cancer Research (Vol. 5)

1 - Liver cancer: Biomarker landscape

Introduction

Etiologic factors

Classification of liver cancer

Hepatocellular carcinoma

Intrahepatic cholangiocarcinoma

Combined HCC-CCA

Biomarkers

Alpha-fetoprotein

Isoforms of AFP

Des-gamma-carboxy prothrombin

Osteopontin

Midkine

Dickkopf protein-1

Glypican-3

Alpha-L-fucosidase

Golgi protein-73

Gamma-glutamyl transferase

Tumor-specific growth factor

Squamous cell carcinoma antigen

Genomic markers

Conclusion

References

2 - Pancreatic cancer: Biomarker landscape

Global statistics

Biomarkers for PC

Serological biomarkers of PC

Glycolipids and proteins

Carbohydrate antigen 19-9

Carcinoembryonic antigen

CA125

CA242

Serum noncoding RNAs

Long noncoding RNAs

Circulating miRNA

Serum liquid biopsy approaches

Exosomes

Circulating tumor cells

Tumor-educated platelets

Urinary biomarkers

Urine protein biomarkers

Urine noncoding RNA

Urine miRNA

Salivary biomarkers

Fecal biomarkers

3 - Heart cancer: Biomarker landscape

Epidemiology

Incidence ad prevalence

Age and gender distribution

Autopsy studies

Geographic and environmental factors

Risk factors

Classification of cardiac tumors

Primary tumor

Benign PCTs

Myxoma

Fibroma

Papillary fibroelastoma.

Rhabdomyoma

Lipoma

Malignant PCT

Sarcoma

Angiosarcoma

Leiomyosarcoma

Rhabdomyosarcoma

Undifferentiated pleomorphic sarcoma

Primary cardiac lymphoma

Secondary or metastatic cardiac tumors

Hematogenous dissemination

Lymphatic spread

Transvenous extension

Direct extension

Cellular mechanism of cardiac cancer

Genetic mutations

Tumor suppressive genes

Oncogenes

Genetic syndromes

Dysregulated cell signaling pathways

Angiogenesis and tumor microenvironment

Epigenetic alteration

DNA methylation

Histone modifications

Noncoding RNA regulation

Chromatin remodeling

Factors affecting cardiac cancer

Biomarkers for cardiac cancer

Validated standard biomarkers for cardiac cancer

Cardiomyocytes

Release and significance

Natriuretic peptides for cardiac cancer

Detection and assessment of tumor-induced cardiotoxicity

Circulating tumor markers

Interleukin-6

Calretinin

Cancer antigen 125

CD31

BNH9

Carboxypeptidase M

Emerging biomarker for detection of cardiac cancer

Myeloperoxidase

Growth differentiation factor-15

Soluble suppressor of tumorigenicity-2

Placental growth factor

Galectin-3

Novel biomarkers

miRNAs

Proteomic and metabolomic biomarkers

Biomarker analysis in cardiac cancer

Detection methodology of cardiac cancer biomarkers

In vitro detection methodology of cardiac cancer biomarkers

Enzyme-linked immunosorbent assay

Chemiluminescent immunoassay

Advantages of CLIA for cardiac biomarker detection

Fluorescence immunoassay

Polymerase chain reaction

Next-generation sequencing

In vivo detection methodology of cardiac cancer biomarkers

Imaging modalities

Cardiac MRI

Nuclear imaging techniques

Imaging with CT

PET scan.

Biopsy and histopathological examination

Transvenous biopsy

Surgical biopsy

Endocardial biopsy

Surgical exploration

Genetic and molecular testing

Multimarker algorithms and machine learning

Challenges and future directions

Challenges faced in aspect for biomarker used in heart cancer

Rarity of cardiac malignancies

Heterogeneity of cardiac tumors

Technical limitations

Integration into clinical practice

Interpreting complex data

Future directions

Large-scale collaborative studies

Precision medicine approaches

Advancements in detection technologies

Artificial intelligence and machine learning

Personalized monitoring and early detection

Exploring new biomarker classes

Regulatory and ethical considerations

4 - Bone cancer: Biomarker landscape

Classification and types of bone cancer

Etiology

Bone cancer statistics

Pathology

Mechanisms of sarcoma development

Applications of biomarkers

Types of biomarkers

Biomarker for bone tumors

MicroRNAs

Transforming growth factor-β

Matrix metalloproteinases

Protooncogene tyrosine-protein kinase (Src)

Apurinic/apyrimidinic endonuclease 1

Hypoxia-inducible factors

Vascular endothelial growth factor-A

SOX9

Periostin

B-cell lymphoma 2

Future perspective

5 - Spleen cancer: Biomarkers landscape

Understanding biomarkers

Definition and role in oncology

Diagnostic biomarker

Prognostic biomarker

Predictive biomarker

Biomarker identification and validation

Spleen cancer biomarkers

Biomarkers for spleen cancer

Prognostic biomarkers

Predictive biomarkers for treatment response

Emerging biomarkers and their potential

Genetic markers.

Clinical applications

Biomarkers in spleen cancer diagnosis

Role in treatment decision making

Personalized medicine

Targeted therapy

Biomarkers in monitoring disease progression and treatment response

Limitations of current biomarkers

Sensitivity and specificity issues

Accessibility and cost

Advances in biomarker research

Technologies in enhancing biomarker discovery

Integrative approaches for biomarker identification

The future of biomarker-based therapy in spleen cancer

Assessing biomarkers: Testing and potential for diagnosis

Validated biomarkers for spleen cancer

Blood-based biomarkers

Genetic biomarkers

Biomarkers under development for spleen cancer

Protein expression profiles

Epigenetic markers

Liquid biopsies

Biomarkers in research and clinical applications

Diagnosis and prognosis []

Treatment response and monitoring []

6 - Brain-CNS cancer: Biomarker landscape

Factors affecting the origination of brain or CNS cancer

Pathophysiology of brain cancer

Biomarkers in diagnosis and prognosis

1p/19q codeletion

IDH-1 and 2

PTEN deletion on chromosome 10

TP53 mutation

MGMT promoter methylation

Ki-67 labeling index

EGFR GF amplification/mutation

Alpha thalassemia-mental retardation syndrome X-linked

v-raf murine sarcoma viral oncogene homolog B1

Diagnostic approach

Biopsy test

Liquid biopsy

Cell-free DNA

Circulating tumor DNA

CSF biomarker

Urine biomarker

Fluorescent tumor markers

Clinical trial on biomarker for brain-CNS cancer

Case study 1

Case study 2

Case study 3

Role of artificial intelligence and modern technology.

Validation of biomarker performance

Preclinical studies

Clinical validation

Analytical validation

Clinical utility Assessment

Statistical and computational validation

Regulatory Approval

Implementation in clinical practice

Postmarket surveillance

Brain cancer biomarkers under development phase

Genomic biomarkers

ATRX mutations

H3K27M mutations

BRAF V600E mutations

Fibroblast growth factor receptor-transforming acidic coiled-coil fusions

Proteomic biomarkers

Tenascin-C

Liquid biopsy biomarkers

Circulating miRNAs

Imaging biomarkers

Hypoxia-induced genes

Radiomics

Epigenetic biomarkers

DNA methylation patterns

Histone modification profiles

Metabolic biomarkers

2-Hydroxyglutarate

Lactate and glutamate

Validated biomarkers of brain cancer

IDH1 and IDH2 mutations

EGFR amplification and EGFRvIII mutation

BRAF V600E mutation

Challenges in validating brain cancer biomarkers

Technical challenges

Heterogeneity of BTs

Sensitivity and specificity

Standardization of assays

Biological challenges

Blood-brain barrier

Dynamic nature of biomarkers

Clinical challenges

Limited patient populations

Ethical considerations

Regulatory environment

Specific application

7 - Skin cancer: Biomarker landscape

Skin cancer

Melanoma

Nonmelanocytic skin cancer

Environmental risk factors

Causes of skin cancer

Prevention and prompt identification

Molecular epidemiology

Examples of biomarkers in skin cancer

Exposure markers

Erythema

Number of UV-induced benign nevi in childhood.

Marker of internal dose.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

0-443-33903-1

OCLC:

1520884258